ObsEva gains on positive late-stage trial results of endometriosis treatment

Obseva SA

06/01/2022 12:03

** U.S. shares of Switzerland-based reproductive drug
developer  OBSV.O  climb 7.7% to $2.22 premarket; among the
three most heavily traded stocks across U.S. exchanges
    ** About 1.33 mln shares changed hands, 1.7x the 25-DMA
    ** Co releases results of a late-stage trial of linzagolix,
its experimental treatment targeting moderate-to-severe
endometriosis-associated pain  urn:newsml:reuters.com:*:nGNE5q2f26
    ** Endometriosis is a condition in which the uterus' inner
lining is found outside the uterus; it affects 1 in 10 women of
reproductive age globally and can cause severe pain, scar tissue
and infertility - WHO
    ** The higher dose in the study, when combined with add-back
therapy (ABT), met both its main goals of reducing painful
periods and non-menstrual pelvic pain at three months
    ** The higher dose with ABT group also met some secondary
goals such as improvement in participants' ability to do daily
activities
    ** The lower dose in the study, which did not include ABT,
did not meet the main goals and most of the secondary goals
    ** Linzagolix was generally well-tolerated; side effects
included headaches, hot flush and fatigue
    

 (Reporting by Ruhi Soni in Bengaluru;)
 ((Ruhi.Soni@thomsonreuters.com ; Twitter: https://twitter.com/ruhithere
 ;;))